Oncoselective Parvoviral Vector-Mediated Gene Therapy of Cancer

Targeting Human Glioblastoma Cells: Comparison of Nine Viruses with Oncolytic Potential

“…Viral replication depends on host cell factors expressed during the S phase of the cell cycle, a requirement that augments, but is not entirely responsible for, the inherent oncotropism of autonomous parvoviruses (13,34,51). Previous studies reported successful targeting and oncolysis of human tumor cell lines (29,49,66). The two strains included in our study, the fibrotropic prototype MVMp and the immunosuppressive strain MVMi, differ in their capsid protein, which is critical for differences in cell targeting and outcome of infection (7,55).…”

LuIII Parvovirus Selectively and Efficiently Targets, Replicates in, and Kills Human Glioma Cells

“…Infection is dependent on spontaneous cell transition through S phase (14), and therefore, nondividing cells such as mature neurons are not susceptible, an important safety feature when targeting glioma in the brain. Additionally, protein expression, DNA replication, and overall propagation of these viruses are generally favored in oncogenically transformed cells, whether transformed by naturally occurring mutations or experimentally transformed by oncogenic viruses, chemical mutation, or sequential transduction with specific oncogenes (9,36,55). In contrast to the Erythrovirus genus (e.g., parvovirus B19), there is no human disease associated with any member of the Parvovirus genus (16).…”